High-density lipoprotein and prostate cancer: An overview

Journal of Epidemiology

Volumn 23, Issue 5, 2013, Pages 313-319

  Kotani, Kazuhiko ^a,b   Sekine, Yoshitaka ^a,c   Ishikawa, Shizukiyo ^b   Ikpot, Imoh Z ^a   Suzuki, Kazuhiro ^c   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ApoA I; Epidemiology; HDL Cholesterol; Prostate tumor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR MARKER;

ARTICLE; BLOOD; HUMAN; JAPAN; MALE; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR; UNITED KINGDOM; UNITED STATES;

CHOLESTEROL, HDL; GREAT BRITAIN; HUMANS; JAPAN; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84886288788     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20130006     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Roberts RO, Bergstralh EJ, Katusic SK, Lieber MM, Jacobsen SJ. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol. 1999;161:529-33.
3. Matsuda T, Matsuda A. Time trends in prostate cancer mortality between 1950 and 2008 in Japan, the USA and Europe based on the WHO mortality database. Jpn J Clin Oncol. 2011;41:1389.
4. Barnard RJ. Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr. 2007;86: s889-93.
5. Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J Clin Oncol. 2010;28:4066-73.
6. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361: 859-64.
7. Dennis LK, Snetselaar LG, Smith BJ, Stewart RE, Robbins ME. Problems with the assessment of dietary fat in prostate cancer studies. Am J Epidemiol. 2004;160:436-44.
8. McGrowder D, Riley C, Morrison EY, Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol. 2011;2011:496925.
9. Magura L, Blanchard R, Hope B, Beal JR, Schwartz GG, Sahmoun AE. Hypercholesterolemia and prostate cancer: a hospital-based case-control study. Cancer Causes Control. 2008; 19:1259-66.
10. Grosman H, Fabre B, Mesch V, Lopez MA, Schreier L, Mazza O, et al. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer. Aging Male. 2010;13:87-92.
11. Mittal A, Sathian B, Chandrasekharan N, Lekhi A, Yadav SK. Role of hypercholesterolemia in prostate cancer-case control study from Manipal Teaching Hospital Pokhara, Nepal. Asian Pac J Cancer Prev. 2011;12:1905-7.
12. Tuohimaa P, Tenkanen L, Syvälä H, Lumme S, Hakulinen T, Dillner J, et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:302-7.
13. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18:2814-21.
14. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009;20:1181-92.
15. Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, Kampman E, et al. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis. 2011;14: 340-5.
16. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011;22:1545-52.
17. Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011;22:1011-9.
18. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004;13:47-55.
19. Prabhat P, Tewari R, Natu SM, Dalela D, Goel A, Tandon P, et al. Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive crosssectional study. Indian J Urol. 2010;26:502-6.
20. Jacobs EJ, Stevens VL, Newton CC, Gapstur SM. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2012;23:1289-96.
21. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41:2887-95.
22. McNamara DJ, Howell WH. Epidemiologic data linking diet to hyperlipidemia and arteriosclerosis. Semin Liver Dis. 1992;12: 347-55.
23. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett. 2010;293:133-43.
24. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012;11:1311-9.
25. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA. 2010;107:19997-20002.
26. Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT. Apolipoprotein mimetic peptides: mechanisms of action as anti-atherogenic agents. Pharmacol Ther. 2011;130:83-91.
27. Jozan S, Faye JC, Tournier JF, Tauber JP, David JF, Bayard F. Interaction of estradiol and high density lipoproteins on proliferation of the human breast cancer cell line MCF-7 adapted to grow in serum free conditions. Biochem Biophys Res Commun. 1985;133:105-12.
28. Rotheneder M, Kostner GM. Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormoneindependent cell lines. Int J Cancer. 1989;43:875-9.
29. Pan B, Ren H, He Y, Lv X, Ma Y, Li J, et al. HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Cancer Res. 2012;18:1246-56.
30. Pan B, Ren H, Ma Y, Liu D, Yu B, Ji L, et al. High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer. 2012;131:70-82.
31. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181: 1998-2008.
32. Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K, et al. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res. 2010; 8:1284-94.
33. Fukuchi J, Hiipakka RA, Kokontis JM, Hsu S, Ko AL, Fitzgerald M, et al. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 2004;64:7682-5.
34. Ni J, Pang ST, Yeh S. Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Prostate. 2007;67: 463-71.
35. Sekine Y, Suzuki K, Remaley AT. HDL and Sphingosine-1- phosphate activate Stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion. Prostate. 2011;71:690-9.